HomeEXECUTIVESErika Laskey Appointed COO Ventec Life Systems

Erika Laskey Appointed COO Ventec Life Systems

Erika Laskey has been appointed Chief Commercial Officer of Ventec Life Systems for the company and member of the new executive leadership team.

“It is a privilege to join the employees of Ventec after witnessing their accomplishments during this past year and the unprecedented collaboration with General Motors which delivered the preferred ventilator to the Strategic National Stockpile of the United States. I look forward to scaling the benefits and business of integrated respiratory care even more broadly to drive exponential growth,” said Laskey.

With over 30 years of experience in the medical technology industry, Laskey is responsible for successfully commercializing a wide range of disruptive technology products that have generated hundreds of millions of dollars in global sales for diverse organizations including both Fortune 100 companies and emerging technology start-ups. As a corporate officer of public and private medical device companies for over 17 years, she brings a deep understanding of respiratory care markets and customers.

“As we build on Ventec’s historic accomplishments and contributions during the COVID-19 crisis, we are entering a new era of commercialization of our enterprise. Erika is an industry veteran who will be instrumental in developing and executing a new corporate vision and commercial presence for Ventec across the continuum of care and we are thrilled to have someone of her caliber and experience lead our commercial team,” said Jim Alwan, President, and Chief Executive Officer, Ventec Life Systems.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy